Sign in

    Alexa Deemer

    Biotechnology Equity Research Associate at Cantor Fitzgerald

    Alexa Deemer is a Biotechnology Equity Research Associate at Cantor Fitzgerald, specializing in covering the biotechnology sector with a focus on clinical-stage pharmaceutical and biopharma companies. She has been cited as covering companies such as ARS Pharmaceuticals, actively participating in earnings calls and industry analysis but has not yet established a public record for performance metrics or analyst rankings on platforms like TipRanks. Deemer began her tenure at Cantor Fitzgerald in recent years and has been engaged in research roles pertinent to the life sciences sector, though publicly available details on her previous experience and precise start date remain limited. Her professional credentials include the Associate designation and, based on regulatory filings, she is likely to hold the required FINRA securities licenses for this role.

    Alexa Deemer's questions to Trevi Therapeutics (TRVI) leadership

    Alexa Deemer's questions to Trevi Therapeutics (TRVI) leadership • Q2 2025

    Question

    Alexa Deemer from Cantor Fitzgerald asked which dose or doses from the CORAL trial the company plans to advance into the Phase 3 study for IPF cough.

    Answer

    James Cassella, Chief Development Officer, identified the 54mg BID dose as a "sweet spot" due to its strong performance across both primary and secondary endpoints. He confirmed that the 54mg BID dose will be a key dose taken forward into the Phase 3 program, subject to FDA alignment.

    Ask Fintool Equity Research AI

    Alexa Deemer's questions to ARS Pharmaceuticals (SPRY) leadership

    Alexa Deemer's questions to ARS Pharmaceuticals (SPRY) leadership • Q4 2024

    Question

    Alexa Deemer from Cantor Fitzgerald asked about the breakdown of the epinephrine market between direct-to-patient retail sales and sales to institutional entities like airlines and schools.

    Answer

    Richard Lowenthal, Co-Founder, President and CEO, and Eric Karas, Chief Commercial Officer, clarified that nearly all current neffy sales are through the retail channel. They noted that the institutional market, such as airlines and restaurants, represents a future growth opportunity not yet included in forecasts, with some entities waiting for the 1mg dose to become available before adoption.

    Ask Fintool Equity Research AI